Chloe Fugère-Desjardins

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition

Stephen J. Morris, D. Durocher, R. Stocco, 2022, Nature.

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

R. Stocco, A. Roulston, Jordan T. F. Young, 2021, Molecular Cancer Therapeutics.

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition

D. Durocher, R. Stocco, A. Roulston, 2021, Nature.